MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- J.B.CHEMICALS - ADCOCK INGRAM (S. Africa)
J.B.CHEMICALS vs ADCOCK INGRAM (S. Africa) - Comparison Results
J.B.CHEMICALS Change
JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More
ADCOCK INGRAM (S. Africa)
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
Financials
 J.B.CHEMICALS  ADCOCK INGRAM |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| J.B.CHEMICALS Mar-18 |
ADCOCK INGRAM Jun-14 |
J.B.CHEMICALS/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 363 | 383 | - | |
| Low | Rs | 255 | 276 | - | |
| Sales per share (Unadj.) | Rs | 169.1 | 113.9 | - | |
| Earnings per share (Unadj.) | Rs | 16.6 | -28.7 | - | |
| Cash flow per share (Unadj.) | Rs | 23.4 | -23.8 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.6 | 0 | - | |
| Book value per share (Unadj.) | Rs | 172.5 | 89.4 | - | |
| Shares outstanding (eoy) | m | 83.57 | 168.78 | - | |
| Bonus/Rights/Conversions | BB | - | - | ||
| Price / Sales ratio | x | 1.8 | 2.9 | 63.2% | |
| Avg P/E ratio | x | 18.6 | -11.5 | -162.1% | |
| P/CF ratio (eoy) | x | 13.2 | -13.9 | -95.3% | |
| Price / Book Value ratio | x | 1.8 | 3.7 | 48.6% | |
| Dividend payout | % | 12.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 25,827 | 55,608 | 46.4% | |
| No. of employees | `000 | 3.8 | 4.3 | 87.9% | |
| Total wages/salary | Rs m | 2,511 | 3,490 | 71.9% | |
| Avg. sales/employee | Rs Th | 3,747.4 | 4,476.9 | 83.7% | |
| Avg. wages/employee | Rs Th | 665.7 | 813.0 | 81.9% | |
| Avg. net profit/employee | Rs Th | 367.8 | -1,128.1 | -32.6% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 14,135 | 19,219 | 73.5% | |
| Other income | Rs m | 366 | 135 | 271.8% | |
| Total revenues | Rs m | 14,501 | 19,354 | 74.9% | |
| Gross profit | Rs m | 2,178 | -3,331 | -65.4% | |
| Depreciation | Rs m | 570 | 829 | 68.7% | |
| Interest | Rs m | 35 | 521 | 6.7% | |
| Profit before tax | Rs m | 1,940 | -4,546 | -42.7% | |
| Minority Interest | Rs m | 0 | -13 | 0.0% | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 552 | 284 | 194.4% | |
| Profit after tax | Rs m | 1,387 | -4,843 | -28.6% | |
| Gross profit margin | % | 15.4 | -17.3 | -88.9% | |
| Effective tax rate | % | 28.5 | -6.2 | -455.7% | |
| Net profit margin | % | 9.8 | -25.2 | -38.9% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 10,470 | 14,076 | 74.4% | |
| Current liabilities | Rs m | 2,749 | 7,920 | 34.7% | |
| Net working cap to sales | % | 54.6 | 32.0 | 170.5% | |
| Current ratio | x | 3.8 | 1.8 | 214.3% | |
| Inventory Days | Days | 55 | 111 | 49.8% | |
| Debtors Days | Days | 78 | 124 | 62.7% | |
| Net fixed assets | Rs m | 5,811 | 8,205 | 70.8% | |
| Share capital | Rs m | 167 | 89 | 187.3% | |
| Net worth | Rs m | 14,416 | 15,085 | 95.6% | |
| Long term debt | Rs m | 0 | 5,301 | 0.0% | |
| Total assets | Rs m | 17,649 | 28,497 | 61.9% | |
| Interest coverage | x | 56.6 | -7.7 | -731.7% | |
| Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 118.8% | |
| Return on assets | % | 8.1 | -15.2 | -53.1% | |
| Return on equity | % | 9.6 | -32.1 | -30.0% | |
| Return on capital | % | 13.7 | -19.8 | -69.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,231 | 1,640 | 75.0% | |
| From Investments | Rs m | -208 | -504 | 41.3% | |
| From Financial Activity | Rs m | -595 | 4,811 | -12.4% | |
| Net Cashflow | Rs m | 427 | 5,948 | 7.2% | |
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.28 Rs / ZAR
Compare J.B.CHEMICALS With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare J.B.CHEMICALS With: DR. REDDYS LAB TTK HEALTHCARE PANACEA BIOTECH WYETH BIOCON
Today's Market
Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Related Views On News
J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)
Feb 6, 2020 | Updated on Feb 6, 2020For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
J.B.CHEMICALS Announces Quarterly Results (4QFY19); Net Profit Up 91.2% (Quarterly Result Update)
May 24, 2019 | Updated on May 24, 2019For the quarter ended March 2019, J.B.CHEMICALS has posted a net profit of Rs 422 m (up 91.2% YoY). Sales on the other hand came in at Rs 4 bn (up 18.9% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
